leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...6869707172737475767778...235236»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Tissue factor expression in colorectal cancer. (On Demand | Level 1, West Hall; Poster Board No. N12) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_913;    
    TME cell infiltration and IO-related biomarkers were enriched in TF-H, with TF exp correlating with endothelial cell abundance. These findings and associations with patient outcomes suggest that TF may be a relevant biomarker and target in CRC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). (On Demand | Level 1, West Hall; Poster Board No. F16) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_783;    
    P2, P3
    In the phase 2 ANCHOR study (NCT03693170), mPFS was 5.8 mo and ORR was 48% for 1L EC + binimetinib in BRAFV600E mCRC...Pts received E 300 mg daily + C 500 mg/m2 every 2 weeks (Q2W) + either mFOLFOX6 Q2W (n=27) or FOLFIRI Q2W (n=30) in 28-day cycles until disease progression or unacceptable toxicity...Expected conclusions will be included in the final abstract. Clinical trial information: NCT04607421.
  • ||||||||||  Prognostic indicators of KRAS G12X mutations in pancreatic cancer. (Available On Demand; Poster Board No. M2) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_592;    
    Immune profiling suggested that the immune contexture in G12R-driven tumors are distinct from G12D as reflected by reduced PDL1 staining, decreased levels of multiple checkpoint receptors. We aim to further explore the molecular basis for these differences with a focus on PI3K and MAPK pathways.
  • ||||||||||  oxaliplatin / Generic mfg.
    Trial completion date, Trial primary completion date:  2 Versus 6 Hour Oxaliplatin Infusions in Patients with Gastrointestinal Cancers (clinicaltrials.gov) -  Dec 13, 2022   
    P2,  N=60, Recruiting, 
    Administering nal-IRI at RD followed by dose escalation in subsequent treatment cycles is safe and does not compromise survival outcomes in selected patients with PDAC receiving nal-IRI plus 5-FU/LV. Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Nov 2022 --> Nov 2023
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Review, Journal:  Advances in Radiation Oncology for Pancreatic Cancer: An Updated Review. (Pubmed Central) -  Dec 12, 2022   
    The use of molecularly targeted agents with radiation to improve radiosensitization has also shown promise in several prospective studies. For resectable and borderline resectable pancreatic cancers (RPC and BRPC), several randomized trials are currently underway to study whether current neoadjuvant regimens using radiation may be improved with the use of the multi-drug regimen FOLFIRINOX or immune checkpoint inhibitors.
  • ||||||||||  oxaliplatin / Generic mfg., gemcitabine / Generic mfg.
    Journal:  Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer. (Pubmed Central) -  Dec 12, 2022   
    Using PamGene technology to decipher gemcitabine's effects on oxaliplatin-resistant cells, we were able to show that gemcitabine counteracts chemoresistance by strongly inhibiting the Akt and src/p38 MAPK pathways, leading to apoptosis induction and cell death. In view of these results, gemcitabine could be an interesting alternative therapy for patients with colorectal cancer not responding to oxaliplatin-based protocols such as FOLFOX.
  • ||||||||||  Biomarker, Journal:  Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. (Pubmed Central) -  Dec 12, 2022   
    Similarly, oncostatin, BDNF, and IP10 cytokines were proven to act as predictive biomarkers regarding PFS, for FOLFIRINOX regimen...Finally, high levels of CD4+ and CD8+ intratumoural infiltration was associated with significantly longer PFS. In conclusion, in this study we were able to identify several prognostic and predictive biomarker candidates in patients diagnosed of resectable or BL PDAC.
  • ||||||||||  Foxy-5 / WntResearch
    Enrollment closed, Trial completion date, Trial primary completion date:  NeoFox: Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer (clinicaltrials.gov) -  Dec 9, 2022   
    P2,  N=100, Active, not recruiting, 
    BRPC and LAPC patients capable of surgery after only receiving neoadjuvant treatment with chemotherapy had higher rates of R0 resection with prolonged median PFS and OS compared with any patient needing combination chemotherapy with radiotherapy. Unknown status --> Active, not recruiting | Trial completion date: Mar 2022 --> Dec 2024 | Trial primary completion date: Mar 2022 --> Dec 2024
  • ||||||||||  Clinical, Journal:  MRI-based radiomics to predict neoadjuvant chemoradiotherapy outcomes in locally advanced rectal cancer: A multicenter study. (Pubmed Central) -  Dec 7, 2022   
    High-probability group (score > 81.82) may have potential benefits from ≥ 4 cycles consolidation chemotherapy (OR: 4.173, 95 % CI: 0.953-18.276, p = 0.058, p = 0.021). We identified and validated a model based on multicenter pre-treatment radiomics to predict ypT0-2 in cT3-4 LARC patients, which may facilitate individualised treatment decision-making for organ-preservation strategies and consolidation chemotherapy.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    FOLFOX/zolbe 🙃 (Twitter) -  Dec 6, 2022   
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial completion date, Trial primary completion date:  FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer (clinicaltrials.gov) -  Dec 6, 2022   
    P2,  N=35, Recruiting, 
    Early outcomes with the regimen are on par with survivals from the FLOT-AIO study. Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ? (Pubmed Central) -  Dec 5, 2022   
    In the second line setting, only FOLFOX (5FU/folinic acid-oxaliplatin) is validated by a phase 3 trial, yet with a very modest benefit on survival; new options using 5FU with nanoliposomal-irinotecan may emerge in the next few years...This strategy opened the way to personalised medicine for patients which are still fit after first-line treatment and the use of targeted inhibitors in first line constitutes a huge challenge with many ongoing trials to improve patients' care. This review exposes the recent clinical trial findings in non-molecularly selected advanced cholangiocarcinoma, offers a focus on how systematic molecular screening should be structured to allow patients to access to personalised medicine, and details which are the therapeutic options accessible in case of actionable alteration.
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Journal:  The full management from first-line to third-line treatments in patients with Her-2-negative advanced gastric cancer. (Pubmed Central) -  Dec 3, 2022   
    The efficacy and survival time of a total of 126 patients who received the first-line treatment with oxaliplatin plus fluoropyrimidine (S-1 or capecitabine or fluorouracil), the second-line treatment with nab-paclitaxel, and the third-line treatment of immune checkpoint inhibitors between September 2019 and December 2021 were analyzed...In addition, 31, 56, and 39 patients received nivolumab, sintilimab, and tislelizumab as a third-line treatment, respectively...The patients who received three lines of treatment had a long survival time, and the efficacy of immunotherapy was not affected by the EBV subtypes in advanced GC. The toxicity was managed, and the concept of full management needs to be confirmed in the future.
  • ||||||||||  TTX-080 / Tizona Therap
    Trial primary completion date, Monotherapy:  TTX-080-001: TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers (clinicaltrials.gov) -  Dec 2, 2022   
    P1a/1b,  N=240, Recruiting, 
    The toxicity was managed, and the concept of full management needs to be confirmed in the future. Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Review, Journal:  Serpentine Supra-venous Hyperpigmentation "Badge of Courage" in Fight Against Cancer: An Brief Review. (Pubmed Central) -  Dec 1, 2022   
    Hyperpigmentation is a rare side effect occurring with 5-FU infusions; it has been reported in 2-5% of patients. Various types of pigmentary abnormalities have been reported with 5-FU use such as diffuse hyperpigmentation of the face and palms, macular pigmentary changes on the palms and soles, hyperpigmentation overlying the superficial venous network also called serpentine supravenous hyperpigmentation (SSH) and persistent supravenous erythematous eruptions (PSEE).(2) Keywords: Serpentine Supra-venous Hyperpigmentation, Dermatological toxicity, Fluorouracil.